Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRX AcelRx Pharmaceuticals		$0.77	$0.43 ▼ $2.78	$14.58M	0.52	137,683 shs	243,500 shs
ATNM Actinium Pharmaceuticals	$1.49 -6.3%	$1.50	$1.03 ▼ $8.64	$46.48M	-0.27	505,432 shs	489,218 shs
GANX Gain Therapeutics	$1.73 -3.9%	$1.86	$0.89 ▼ $3.19	$51.81M	0.11	312,155 shs	220,421 shs
IFRX InflaRx	$0.78 -2.0%	$1.28	$0.71 ▼ $2.82	$52.63M	1.29	283,348 shs	819,458 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRX AcelRx Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ATNM Actinium Pharmaceuticals	-6.29%	-18.58%	+2.05%	+21.14%	-81.72%
GANX Gain Therapeutics	-3.89%	-9.90%	-6.99%	-18.01%	-18.01%
IFRX InflaRx	-2.00%	-5.55%	-57.39%	-34.12%	-50.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	1.1964 of 5 stars	3.4	2.0	0.0	0.0	0.0	0.0	0.6
GANX Gain Therapeutics	2.2954 of 5 stars	3.6	3.0	0.0	0.0	2.8	0.0	0.6
IFRX InflaRx	3.388 of 5 stars	4.5	3.0	0.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRX AcelRx Pharmaceuticals	0.00	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	168.46% Upside
GANX Gain Therapeutics	3.17	Buy	$8.20	373.99% Upside
IFRX InflaRx	3.00	Buy	$6.60	741.84% Upside

Current Analyst Ratings Breakdown

Latest ACRX, GANX, ATNM, and IFRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	IFRX InflaRx	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/8/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
4/29/2025	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/1/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/28/2025	GANX Gain Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/26/2025	IFRX InflaRx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/25/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRX AcelRx Pharmaceuticals	$1.77M	0.00	N/A	N/A	$2.65 per share	0.00
ATNM Actinium Pharmaceuticals	$81K	573.85	N/A	N/A	$1.31 per share	1.14
GANX Gain Therapeutics	$50K	1,036.13	N/A	N/A	$0.97 per share	1.78
IFRX InflaRx	$129.75K	405.64	N/A	N/A	$1.89 per share	0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRX AcelRx Pharmaceuticals	$47.76M	-$2.23	N/A	N/A	N/A	N/A	-81.54%	-46.02%	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
GANX Gain Therapeutics	-$22.27M	-$0.86	N/A	N/A	N/A	N/A	-203.91%	-128.05%	8/6/2025 (Estimated)
IFRX InflaRx	-$46.18M	-$0.82	N/A	N/A	N/A	-33,362.70%	-65.98%	-56.86%	8/6/2025 (Estimated)

Latest ACRX, GANX, ATNM, and IFRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million
3/27/2025	Q4 2024	GANX Gain Therapeutics	-$0.18	-$0.11	+$0.07	-$0.11	N/A	N/A
3/20/2025	Q4 2024	IFRX InflaRx	-$0.27	-$0.09	+$0.18	-$0.09	$0.13 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRX AcelRx Pharmaceuticals	N/A	4.04	4.04
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
GANX Gain Therapeutics	0.04	2.99	2.99
IFRX InflaRx	N/A	5.31	4.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRX AcelRx Pharmaceuticals	19.79%
ATNM Actinium Pharmaceuticals	27.50%
GANX Gain Therapeutics	11.97%
IFRX InflaRx	42.39%

Insider Ownership

Company	Insider Ownership
ACRX AcelRx Pharmaceuticals	3.00%
ATNM Actinium Pharmaceuticals	6.00%
GANX Gain Therapeutics	7.18%
IFRX InflaRx	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRX AcelRx Pharmaceuticals	19	16.95 million	16.44 million	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
GANX Gain Therapeutics	20	29.95 million	23.42 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable

ACRX, GANX, ATNM, and IFRX Headlines

Recent News About These Companies

Cantor Fitzgerald Comments on InflaRx FY2026 Earnings

June 12 at 2:49 AM | americanbankingnews.com

Brokers Issue Forecasts for InflaRx FY2026 Earnings

June 10, 2025 | marketbeat.com

InflaRx (NASDAQ:IFRX) Sees Large Decline in Short Interest

June 4, 2025 | marketbeat.com

InflaRx stock rating cut, price target slashed to $2 by Raymond James

May 30, 2025 | investing.com

InflaRx Earnings Estimates, EPS & Revenue | NASDAQ:IFRX | Benzinga

May 30, 2025 | benzinga.com

Oppenheimer Has Lowered Expectations for InflaRx (NASDAQ:IFRX) Stock Price

May 30, 2025 | marketbeat.com

InflaRx’s Strategic Shift to INF904: A Promising Focus Amidst Early-Stage Uncertainty

May 29, 2025 | tipranks.com

InflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 28, 2025 | finanznachrichten.de

PG rating: Inflarx review declares phase III bomb

May 28, 2025 | bioworld.com

InflaRx ditches vilobelimab Phase III trial in PG

May 28, 2025 | thepharmaletter.com

InflaRx plunges on plans to halt studies into lead asset in rare skin disorder

May 28, 2025 | msn.com

InflaRx Stock (IFRX) Plummets 55% on Clinical Failure

May 28, 2025 | tipranks.com

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

May 28, 2025 | benzinga.com

InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp

May 28, 2025 | marketbeat.com

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma ...

May 28, 2025 | gurufocus.com

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 28, 2025 | globenewswire.com

InflaRx to Participate in Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in InflaRx (NASDAQ:IFRX)

May 16, 2025 | marketbeat.com

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)

May 11, 2025 | sg.finance.yahoo.com

Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation

May 9, 2025 | msn.com

Oppenheimer Initiates Coverage on InflaRx (IFRX) with "Outperform" Rating | IFRX ...

May 8, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRX, GANX, ATNM, and IFRX Company Descriptions

AcelRx Pharmaceuticals NASDAQ:ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Actinium Pharmaceuticals NYSE:ATNM

$1.49 -0.10 (-6.29%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.49 0.00 (0.00%)

As of 06/13/2025 07:08 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Gain Therapeutics NASDAQ:GANX

$1.73 -0.07 (-3.89%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.05 (+2.83%)

As of 06/13/2025 07:56 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

InflaRx NASDAQ:IFRX

$0.78 -0.02 (-2.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.78 0.00 (-0.38%)

As of 06/13/2025 07:16 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time